Xuetao Wang1, Marsha Taylor2, Linda Hoang3, Judi Ekkert4, Craig Nowakowski5, Jason Stone6, Greg Tone7, Steven Trerise6, Ana Paccagnella8, Titus Wong9, Eleni Galanis10. 1. Faculty of Health Sciences, Simon Fraser University, Burnaby; 2. British Columbia Centre for Disease Control, University of British Columbia, Vancouver; 3. British Columbia Public Health Microbiology and Reference Laboratory, University of British Columbia, Vancouver; ; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver; 4. Interior Health, Kelowna, University of British Columbia, Vancouver, British Columbia; 5. Vancouver Island Health, Victoria, University of British Columbia, Vancouver, British Columbia; 6. Fraser Health, Surrey, University of British Columbia, Vancouver, British Columbia; 7. Northern Health, Prince George, University of British Columbia, Vancouver, British Columbia; 8. British Columbia Public Health Microbiology and Reference Laboratory, University of British Columbia, Vancouver; 9. Division of Medical Microbiology and Infection Control, Department of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia; 10. British Columbia Centre for Disease Control, University of British Columbia, Vancouver; ; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia.
Abstract
INTRODUCTION: Shiga toxin-producing Escherichia coli (STEC) are major foodborne agents that have the potential to cause severe enteric illnesses and large outbreaks worldwide. Several studies found non-O157 infections to be clinically milder than O157 STEC infections. OBJECTIVE: To compare the clinical and epidemiological profiles of O157 and non-O157 STEC human infections in British Columbia (BC). METHODS: All STEC cases reported in BC from 2009 to 2011 by four local health authorities were included in the study. Cases were classified according to STEC serotype based on laboratory information. Information was gathered via case interview forms. Data analysis included the χ(2) test and Mann-Whitney test; P<0.05 was considered to be statistically significant. RESULTS: A total of 260 STEC cases were reported, including 154 (59.2%) O157 cases, 63 (24.2%) non-O157 cases and 43 (16.5%) STEC cases with no serotype identified. Hospitalization rate was higher and duration of hospitalization was significantly longer for O157 cases compared with non-O157 cases, but other clinical features were not significantly different. Patients with non-O157 infections were significantly more likely to have travelled outside Canada, less likely to report food exposure at social gatherings and more likely to consume bagged greens and cheese. DISCUSSION: O157 is the predominant O serotype in BC and appeared to be more clinically severe than non-O157 STEC infections. However, the true incidence and severity of non-O157 remain unknown due to our current inability to detect all non-O157 cases. The present study and the literature suggest the need to identify more predictive virulence factors because serotype does not consistently predict disease severity.
INTRODUCTION: Shiga toxin-producing Escherichia coli (STEC) are major foodborne agents that have the potential to cause severe enteric illnesses and large outbreaks worldwide. Several studies found non-O157 infections to be clinically milder than O157 STEC infections. OBJECTIVE: To compare the clinical and epidemiological profiles of O157 and non-O157 STEC humaninfections in British Columbia (BC). METHODS: All STEC cases reported in BC from 2009 to 2011 by four local health authorities were included in the study. Cases were classified according to STEC serotype based on laboratory information. Information was gathered via case interview forms. Data analysis included the χ(2) test and Mann-Whitney test; P<0.05 was considered to be statistically significant. RESULTS: A total of 260 STEC cases were reported, including 154 (59.2%) O157 cases, 63 (24.2%) non-O157 cases and 43 (16.5%) STEC cases with no serotype identified. Hospitalization rate was higher and duration of hospitalization was significantly longer for O157 cases compared with non-O157 cases, but other clinical features were not significantly different. Patients with non-O157 infections were significantly more likely to have travelled outside Canada, less likely to report food exposure at social gatherings and more likely to consume bagged greens and cheese. DISCUSSION: O157 is the predominant O serotype in BC and appeared to be more clinically severe than non-O157 STEC infections. However, the true incidence and severity of non-O157 remain unknown due to our current inability to detect all non-O157 cases. The present study and the literature suggest the need to identify more predictive virulence factors because serotype does not consistently predict disease severity.
Authors: Laura H Thompson; Sandra Giercke; Carole Beaudoin; David Woodward; John L Wylie Journal: Can J Infect Dis Med Microbiol Date: 2005-11 Impact factor: 2.471
Authors: John T Brooks; Evangeline G Sowers; Joy G Wells; Katherine D Greene; Patricia M Griffin; Robert M Hoekstra; Nancy A Strockbine Journal: J Infect Dis Date: 2005-09-14 Impact factor: 5.226
Authors: Guy Cornu; Willem Proesmans; Anne Dediste; Frédérique Jacobs; Johan Van De Walle; An Mertens; José Ramet; Sabine Lauwers Journal: Clin Microbiol Infect Date: 1999-01 Impact factor: 8.067
Authors: C Jenkins; G A Willshaw; J Evans; T Cheasty; H Chart; D J Shaw; G Dougan; G Frankel; H R Smith Journal: J Med Microbiol Date: 2003-11 Impact factor: 2.472
Authors: Michelle McPherson; Karin Lalor; Barry Combs; Jane Raupach; Russell Stafford; Martyn D Kirk Journal: Clin Infect Dis Date: 2009-07-15 Impact factor: 9.079
Authors: Elaine Scallan; Robert M Hoekstra; Frederick J Angulo; Robert V Tauxe; Marc-Alain Widdowson; Sharon L Roy; Jeffery L Jones; Patricia M Griffin Journal: Emerg Infect Dis Date: 2011-01 Impact factor: 6.883
Authors: Lu Ya Ruth Wang; Cassandra C Jokinen; Chad R Laing; Roger P Johnson; Kim Ziebell; Victor P J Gannon Journal: Front Microbiol Date: 2018-08-31 Impact factor: 5.640